TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC).
Christos Vaklavas
No relevant relationships to disclose
Vandana Gupta Abramson
No relevant relationships to disclose
Nancy U. Lin
No relevant relationships to disclose
Minetta C. Liu
No relevant relationships to disclose
Hope S. Rugo
No relevant relationships to disclose
Rita Nanda
No relevant relationships to disclose
Anna Maria Storniolo
No relevant relationships to disclose
Tiffany A. Traina
No relevant relationships to disclose
Yufeng Li
No relevant relationships to disclose
Sujata Patil
No relevant relationships to disclose
Daniel F. Hayes
Consultant or Advisory Role - Biomarker Strategies ; Inbiomotion
Stock Ownership - Medivation; OncImmune
Research Funding - Janssen Oncology; Novartis; Pfizer; Veridex
Other Remuneration - Veridex (Intellectual Property Interests)
Catherine H. Van Poznak
Employment or Leadership Position - Bone and Cancer Foundation; Paget Foundation
Research Funding - NIH - NIDCR; Translational Breast Cancer Research Consortium
Other Remuneration - NCCN (Educational Presentation Development); School of Breast Oncology (Educational Presentation Development); UpToDate (Intellectual Property Interests); Western Michigan University School of Medicine (Educational Presentation Development)
Julie R. Nangia
No relevant relationships to disclose
William Johnson Irvin
No relevant relationships to disclose
Helen Krontiras
No relevant relationships to disclose
Jennifer F. De Los Santos
No relevant relationships to disclose
Paul Haluska
No relevant relationships to disclose
Antonio C. Wolff
No relevant relationships to disclose
Andres Forero-Torres
Research Funding - Daiichi Sankyo